News & Updates
Filter by Specialty:
Low-dose spironolactone safe, effective in T2D patients with chronic kidney disease
Treatment with low-dose spironolactone results in reduced albuminuria without causing hyperkalaemia in patients with type 2 diabetes (T2D), reports a study.
Low-dose spironolactone safe, effective in T2D patients with chronic kidney disease
19 Sep 2023Study confirms causal link between plasma cortisol and hypertension
Individuals with higher genetically predicted plasma cortisol appear to have greater odds of hypertension, according to a Mendelian randomization analysis.
Study confirms causal link between plasma cortisol and hypertension
18 Sep 2023Does UV-B phototherapy increase the risk of skin cancer in AD patients?
Ultraviolet (UV)-B phototherapy does not appear to increase the risk of skin cancer in patients with atopic dermatitis (AD), reveals a study.
Does UV-B phototherapy increase the risk of skin cancer in AD patients?
18 Sep 2023Chloride-potassium assessment helps diagnose thiazide-associated hyponatraemia
Assessment of apparent strong ion difference (aSID), potassium, and chloride in urine is a useful tool for classifying patients with volume-depleted thiazide-associated hyponatraemia (TAH) requiring fluid substitution relative to those with syndrome of inappropriate antidiuresis (SIAD)-like presentation warranting fluid restriction, according to a recent study.
Chloride-potassium assessment helps diagnose thiazide-associated hyponatraemia
18 Sep 2023Bimekizumab safe, effective in moderate-to-severe plaque psoriasis
The high clinical response levels achieved with bimekizumab over 48 weeks persist up to week 96 in patients with moderate-to-severe plaque psoriasis, results of the BE RADIANT phase IIIb trial have shown. In addition, those on secukinumab who switched to bimekizumab have achieved similar responses at 96 weeks.